Gyorgy Petrovics is a Research Professor and Senior
Scientist at the Henry M. Jackson Foundation for the Advancement of Military
Medicine in support of the Center for Prostate Disease Research (CPDR) and
Murtha Cancer Center Research Program (MCCRP), Uniformed Services University of
the Health Sciences. He has an academic appointment at the Uniformed Services
University (USU), F. Edward Hébert School of Medicine, in the USU-Walter Reed
Department of Surgery. He earned his Ph.D. and “Doctoris Universitatis” degrees
in 1992 and 1997 in Hungary, then completed a Junior Fellowship at the Max
Planck Institute, Germany, a Postdoctoral Fellowship at CNRS, France, and a
Fogarty Fellowship at the Douglas Lowy Laboratory, NCI/NIH, USA. He has played
a key scientific leadership role in developing and accumulating valuable
resources, including biobank specimens and infrastructure (multidisciplinary
collaborations), over 20 years at CPDR. He was the first to notice and highlight
the widespread overexpression of the ERG oncogene in prostate cancer, a major
prostate cancer driver gene. He also recognized early on the disparate expression
of ERG and other genes between African American and Caucasian American prostate
tumors. He discovered that a novel prostate-specific gene called PCGEM1 is a
long non-coding RNA (lncRNA) gene. Dr. Petrovics developed novel prostate
cancer biomarker panels and assay platforms to translate into clinical use for
the benefit of patients.
Gyorgy Petrovics is a Research Professor and Senior
Scientist at the Henry M. Jackson Foundation for the Advancement of Military
Medicine in support of the Center for Prostate Disease Research (CPDR) and
Murtha Cancer Center Research Program (MCCRP), Uniformed Services University of
the Health Sciences. He has an academic appointment at the Uniformed Services
University (USU), F. Edward Hébert School of Medicine, in the USU-Walter Reed
Department of Surgery. He earned his Ph.D. and “Doctoris Universitatis” degrees
in 1992 and 1997 in Hungary, then completed a Junior Fellowship at the Max
Planck Institute, Germany, a Postdoctoral Fellowship at CNRS, France, and a
Fogarty Fellowship at the Douglas Lowy Laboratory, NCI/NIH, USA. He has played
a key scientific leadership role in developing and accumulating valuable
resources, including biobank specimens and infrastructure (multidisciplinary
collaborations), over 20 years at CPDR. He was the first to notice and highlight
the widespread overexpression of the ERG oncogene in prostate cancer, a major
prostate cancer driver gene. He also recognized early on the disparate expression
of ERG and other genes between African American and Caucasian American prostate
tumors. He discovered that a novel prostate-specific gene called PCGEM1 is a
long non-coding RNA (lncRNA) gene. Dr. Petrovics developed novel prostate
cancer biomarker panels and assay platforms to translate into clinical use for
the benefit of patients.